Successful targeting of immune checkpoints including cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) has achieved durable regressions in a wide range of human cancers (referred to as checkpoint blockade). This evidence concerns the gene PDCD1 and cancer.